Non-Alcoholic Steatohepatitis Biomarkers Market Size, Share, Trends, Industry Report & Forecast 2028

Non-Alcoholic Steatohepatitis Biomarkers Market: Overview

The global non-alcoholic steatohepatitis biomarkers market size was worth USD 1,218.5 Million in 2021 and is estimated to grow to USD 5,234.6 Million by 2028, with a compound annual growth rate (CAGR) of approximately 27.5% over the forecast period. The report analyzes the non-alcoholic steatohepatitis biomarkers market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the non-alcoholic steatohepatitis biomarkers market.

Request Free Sample

Non-Alcoholic Steatohepatitis Biomarkers Market:

Non-alcoholic fatty liver disease (NAFLD), which develops when an excessive amount of fat builds up in the liver and causes inflammation & damage that results in liver scarring, progresses to non-alcoholic steatohepatitis (NASH). A biomarker is an indication for assessing both pathogenic and normal biological processes in the body and is considered the most accurate diagnostic tool for determining biological conditions. Noninvasive technologies are referred to as biomarker tools used to diagnose NASH conditions. The reviewed market is expanding as a result of the rising prevalence of metabolic comorbidities and NASH in the general population.

In addition, increased awareness of non-alcoholic fatty liver disease would open up new opportunities for the global non-alcoholic steatohepatitis biomarkers market size over the anticipated period. NAFLD can be correctly diagnosed using imaging techniques such as computed tomography, magnetic resonance imaging, and ultrasound scanning. These methods, however, are ineffective for detecting liver fibrosis or NASH. In the upcoming years, it is projected that these factors will increase demand for noninvasive diagnostic tools, such as serum biomarkers, for disease detection, thereby fueling the growth of the non-alcoholic steatohepatitis biomarkers market share. A surge in projects to create NASH medications creates a solid foundation for market expansion. The development of the global non-alcoholic steatohepatitis biomarkers market is being constrained by the adverse effects of NASH therapies as well as the absence of sophisticated diagnostic testing for NAFLD.

Request Free Sample

Key Insights

• As per the analysis shared by our research analyst, the global non-alcoholic steatohepatitis biomarkers market value is to grow at a CAGR of 27.5% over the forecast period. 

• In terms of revenue, the global non-alcoholic steatohepatitis biomarkers market size was valued at around USD 1,218.5 million in 2021 and is projected to reach USD 5,234.6 million by 2028. 
• The market for non-alcoholic steatohepatitis biomarkers is being driven by the rising prevalence of non-alcoholic steatohepatitis (NASH), and a growing patient base suffering from diabetes and obesity.
• As of 2021, serum biomarkers type held the majority of the market.
• In 2021, the diagnostic center's industry dominated the market for non-alcoholic steatohepatitis biomarkers based on end-user.
• In 2021, North America dominated the market for non-alcoholic steatohepatitis biomarkers, and it is predicted that this trend will persist over the coming years.

COVID-19 Impact:

The global non-alcoholic steatohepatitis biomarkers market growth was negatively impacted by Covid-19. Restrictions on travel and cargo movement severely disrupted the supply chain. As a result, during a few peak months, there was a market shortage of medications and medical supplies. Additionally, the temporary closure of production facilities to stop the virus's spread led to decreased output and employee layoffs. Additionally, fewer patients were attending the diagnostic centers due to travel limitations, reducing the demand for non-alcoholic steatohepatitis biomarkers. Nevertheless, the market has quickly recovered in the post-Covid period and is probably about to outpace the prior growth rate.

Non-Alcoholic Steatohepatitis Biomarkers Market: Growth Drivers

Increase in NAFLD and NASH prevalence is predicted to drive global market

Non-alcoholic liver illnesses are now occurring with greater frequency. NAFLD and other liver disorders are more common in patients with obesity and type 2 diabetes. The prevalence of liver illnesses not caused by alcohol is predicted to rise. It is projected that rising pollution levels and lifestyle changes will increase the prevalence of non-alcoholic liver disorders. Consequently, this will fuel the market for non-alcoholic steatohepatitis biomarkers.

Non-Alcoholic Steatohepatitis Biomarkers Market: Restraints

Lack of professionals and high infrastructure requirements is restraining the market growth

The lack of professionals is a major factor that is expected to limit the growth for the global non-alcoholic steatohepatitis biomarkers market Segmentation . The high cost of imaging testing is another issue that restrains market expansion. The analysis period's expansion of the global market may be constrained by the requirement for substantial expenditure on drug development. In addition, strict government regulations by the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), as well as the side effects connected with medications, are some of the factors impeding the growth of the global non-alcoholic steatohepatitis biomarkers market.

Non-Alcoholic Steatohepatitis Biomarkers Market: Segmentation

The global non-alcoholic steatohepatitis biomarkers market has been segmented into biomarker type, end-user, and region.

Based on biomarker type, the global non-alcoholic steatohepatitis biomarkers market is segmented into serum biomarkers, biomarker panels, fibrosis biomarkers, and imaging biomarkers. As of 2021, serum biomarkers held the majority of the market. These are the diagnostic techniques that are most frequently used to find NASH. Leptin, ghrelin, tumor necrosis factor-alpha, free fatty acids, apolipoprotein B, apolipoprotein A1, and adiponectin are some developing goods that can provide useful services in addition to the existing ones and are anticipated to drive the segment's growth. Serum biomarkers are also projected to dominate the segment due to their advantages, such as their capacity to distinguish between basic steatosis and NASH and provide effective results.

Based on end-user, the global non-alcoholic steatohepatitis biomarkers market industry analysis is segmented into hospitals, diagnostic centers, and others. In 2021, the diagnostic center industry dominated the market for non-alcoholic steatohepatitis biomarkers. With greater knowledge of the indications for early diagnosis and effective treatment of non-alcoholic steatohepatitis (NASH), the diagnostic centers' segment dominated the global non-alcoholic steatohepatitis biomarkers market in 2021. The diagnostic center's segment is projected to be driven by the availability of technologically sophisticated instruments like biomarkers tests in diagnostic centers combined with the presence of expertise.

Non-Alcoholic Steatohepatitis Biomarkers Market: Regional LandscapeMarket Size, Share, Trends, Growth & Forecast

North America dominated the non-alcoholic steatohepatitis biomarkers market in 2021

The market for non-alcoholic steatohepatitis biomarkers is expanding in North America due to causes, including supportive government policies, increased incidence of infectious disorders, cardiovascular conditions, and diabetes. Research and development funding for non-alcoholic steatohepatitis biomarkers is strong, which supports medication development efforts and fosters industry expansion. Additionally, U.S. government rules encourage research into the creation of innovative compounds, which is expected to spur industrial expansion. In this area, it is predicted that the NASH biomarkers market will grow at a profitable CAGR.

Non-Alcoholic Steatohepatitis Biomarkers Market: Competitive Landscape 

Some of the main competitors dominating the global non-alcoholic steatohepatitis biomarkers market include- Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers, ONE WAY LIVER, S.L, Prometheus Laboratories Inc, and Gilead Sciences Ltd.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Report Scope:

Global Non-Alcoholic Steatohepatitis Biomarkers Market is segmented as follows:

By Biomarker Type

• Serum Biomarkers
• Biomarker Panels
• Fibrosis Biomarkers
• Imaging Biomarkers
• Others

By End-User

• Hospitals
• Diagnostic Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa